Promising Type 1 Diabetes Treatment Advances with FDA Pre-IND Meeting
Kadimastem and iTolerance have successfully completed a pre-IND meeting with the FDA for iTOL-102, a potential breakthrough treatment for Type 1 Diabetes that could eliminate the need for lifelong immunosuppression. The collaboration marks a significant milestone in developing an innovative cell therapy approach.
Read the full story



















